Plant-Derived and Endogenous Cannabinoids in Epilepsy

Area of Science:

• Neuroscience
• Pharmacology
• Epileptology

Background:

• Cannabis, a long-used psychotropic drug, possesses known anticonvulsant properties.
• The endocannabinoid system's role in epilepsy provides a biochemical basis for cannabis's effects.
• Epilepsy treatment remains a significant challenge, driving research into alternative therapies.

Purpose of the Study:

• To review the efficacy of cannabis in treating epilepsy in both adult and pediatric populations.
• To explore the biochemical mechanisms involving the endocannabinoid system in epilepsy.
• To assess the general tolerability and adverse events associated with cannabis-based epilepsy treatments.

Main Methods:

• Review of anecdotal reports and existing clinical trials on cannabis for epilepsy.
• Analysis of the endocannabinoid system's involvement in epileptic conditions.
• Investigation into the side effect profiles and tolerability of cannabis use.

Main Results:

• Anecdotal reports and some clinical trials suggest cannabis has anticonvulsant properties.
• Cannabis may be effective for partial epilepsies and generalized tonic-clonic seizures.
• Cessation of cannabis use in epilepsy patients can lead to seizure recurrence, while resumption controls seizures.

Conclusions:

• There is anecdotal evidence supporting the potential efficacy of cannabis in epilepsy management.
• Concerns persist regarding cannabis efficacy, potency, availability, dosing, and side effects, including developmental impacts.
• Increased patient and public advocacy for legalization contrasts with ongoing scientific and clinical uncertainties.